Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG dose comparison in HLA-matched allogeneic hematopoietic stem cell transplantation for thalassemia major
ChiCTR-IPR-15005779Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Mar 2015
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin in beta thalassemia (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Overall survival and Disease-free survival. Planned start Mar 2015; status: not yet recruiting.
02
Drugs
antithymocyte globulin
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on ChiCTR-IPR-15005779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005779.